APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
← catalyst calendarSponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →. With Suzhou Yasheng Pharmaceutical Co., Ltd..
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
95estimated
Sites
3
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-05-26 | actual | When the study began enrolling |
| Primary completion | Apr 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2021-03-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-02-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Liposarcoma
- Advanced Solid Tumor
Interventions
- Drug: APG-115
- Drug: Toripalimab
Primary outcomes
what the primary-completion date above is the date OFDose Limiting Toxicity (Phase I)
measured 21 days
Recommended Phase II Dose
measured 21 days
Overall Response Rate (Phase II)
measured up to 12 months
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed